A groundbreaking study from the University of Macau has unveiled a novel mechanism underlying resistance to PARP inhibitors (PARPi) in BRCA1-deficient breast cancer, opening new avenues for overcoming therapeutic challenges. Breast cancer remains the most prevalent cancer among women globally, with hereditary forms accounting for roughly 10% of cases. Notably, approximately 60% of hereditary breast cancers harbor mutations in the BRCA1 or BRCA2 genes. BRCA1, a critical genome caretaker, orchestrates high-fidelity DNA double-strand break repair via homologous recombination (HR)—a pathway whose inactivation fosters cancer development and poses significant treatment challenges.
Targeting the vulnerability of BRCA-deficient tumors, PARP inhibitors like Olaparib have revolutionized cancer therapy by exploiting synthetic lethality. These agents inhibit PARP1, a key enzyme responsible for repairing single-strand breaks, thereby overwhelming HR-deficient cells with DNA damage leading to cell death. Despite promising clinical outcomes, intrinsic resistance to PARPi has emerged as a formidable obstacle limiting their long-term efficacy. Detailed mechanistic insights into resistance pathways are crucial to enhancing therapeutic success and patient survival.
Recent research has shifted focus toward the interplay between DNA damage responses and innate immunity. DNA damage induces accumulation of cytosolic nucleic acids, which can activate immune signaling pathways such as the cGAS-STING axis. This pathway propagates type I interferon production, fostering an antitumor microenvironment. Intriguingly, DNA damage can also lead to intracellular accumulation of double-stranded RNA (dsRNA), mimicking viral infection and triggering potent antiviral immune responses. However, the precise molecular events connecting PARP inhibition, dsRNA accumulation, and innate immunity remained enigmatic until now.
The newly published study by Chuxia Deng and Edwin Cheung’s team elucidates that PARPi treatment significantly perturbs spliceosome function in tumor cells. Employing advanced functional proteomics, they discovered that PARP1 interacts more robustly with the spliceosome component SF3B1 upon PARP inhibition. This aberrant interaction disrupts normal splicing processes, resulting in widespread alternative mRNA splicing and the subsequent build-up of dsRNA species within the cancer cell cytosol.
Activation of antiviral mimicry mechanisms follows, whereby dsRNA accumulation elicits innate immune signaling cascades typically reserved for viral defense. This response potentiates antitumor immunity by engaging cytosolic viral RNA sensors and downstream effectors. Surprisingly, the study reveals that the intrinsic ability of tumor cells to activate these immune pathways is critically modulated by BRCA1 through regulation of interferon regulatory factor 3 (IRF3). IRF3 acts as a master transcription factor in antiviral responses, and BRCA1 loss results in its repression.
This suppression of IRF3 in BRCA1-deficient breast cancer cells dampens the dsRNA-triggered immune activation induced by PARP inhibition. By silencing this immune axis, tumor cells evade immune-mediated elimination, thereby manifesting intrinsic resistance to PARPi. This refined understanding identifies BRCA1 not only as a DNA repair protein but also as a pivotal regulator of tumor-intrinsic innate immunity—a dimension previously unappreciated.
Exploiting this vulnerability, the researchers explored combination therapies that could resensitize resistant tumors. They found that administering polyinosinic:polycytidylic acid, poly(I:C)—a synthetic dsRNA analog—potently stimulates antiviral pathways by mimicking viral dsRNA, thereby amplifying immune signaling. Poly(I:C) treatment restored the immune activation suppressed by BRCA1 loss and markedly enhanced the antitumor efficacy of PARPi in in vivo models, suggesting therapeutic promise.
This combinatory strategy leverages tumor cell-intrinsic signaling to elicit robust innate immunity, circumventing conventional resistance mechanisms. Importantly, the findings suggest that manipulating dsRNA sensing and interferon pathways can transform “cold” tumors into “hot,” immune-responsive ones, enhancing immunogenicity and therapeutic susceptibility. Such approaches could revolutionize treatment paradigms for BRCA1-mutated breast cancers and potentially other homologous recombination-deficient malignancies.
From a mechanistic perspective, these findings underscore a complex interplay between genome maintenance, RNA processing, and immune surveillance. PARP1’s role extends beyond DNA repair, influencing RNA splicing machinery and thereby shaping the tumor immune landscape. The dysregulation observed in BRCA1-deficient contexts exemplifies how genomic instability can subvert immune defenses, promoting tumor progression and treatment failure.
This research also bridges gaps between cancer biology and immunology, highlighting innate immune pathways as therapeutic targets in genotoxic stress contexts. It encourages further exploration of antiviral mimicry in cancer immunotherapy, potentially integrating PARPi with immune agonists for synergistic effects. Future studies may delve into optimizing dosing, timing, and delivery of dsRNA analogs combined with PARPi to maximize patient outcomes.
The translational implications are profound. Identifying biomarkers such as IRF3 expression or spliceosome alterations might guide personalized therapy, selecting patients likely to benefit from combination treatments. Moreover, this work offers a blueprint for overcoming drug resistance, a predominant cause of cancer relapse, by reactivating dormant immune pathways within tumors.
In conclusion, this pivotal study reveals that PARP inhibitors induce antitumor innate immune responses through dsRNA accumulation, but BRCA1 deficiency impairs this mechanism by repressing IRF3, thereby conferring resistance. The addition of poly(I:C) as an immune stimulant effectively reverses resistance and potentiates PARPi efficacy in BRCA1-deficient breast cancer models. These findings not only redefine BRCA1’s role in cancer immunity but also highlight innovative strategies to enhance precision oncology. As this research gains traction, it promises to reshape therapeutic approaches, offering new hope for patients facing resistant breast cancers.
Subject of Research: Not applicable
Article Title: Tumor cell intrinsic dsRNA innate immune response triggered by PARP inhibitor is compromised in BRCA1-deficient breast cancer by repressing IRF3
News Publication Date: 10-Jan-2026
Web References: 10.1093/procel/pwaf104
Image Credits: HIGHER EDUCATION PRESS
Keywords: BRCA1, PARP inhibitors, innate immunity, dsRNA, antiviral mimicry, spliceosome, IRF3, breast cancer, drug resistance, homologous recombination deficiency, poly(I:C)
Tags: BRCA1-deficient breast cancer resistancecGAS-STING pathway in DNA damageDNA damage response and immune signalingdouble-stranded RNA immune responsehereditary breast cancer geneticshomologous recombination repair deficiencyinnate immunity in breast cancerIRF3 suppression in cancerOlaparib resistance in BRCA mutationsPARP inhibitor resistance mechanismssynthetic lethality in cancer therapytargeting PARP1 in cancer treatment
